Literature DB >> 28283283

Drug development in prostate cancer: time to embrace RECIST?

Guru Sonpavde1, Andrew J Armstrong2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28283283     DOI: 10.1016/S1470-2045(17)30149-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Authors:  Guru Sonpavde; Gregory R Pond; Melissa Plets; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Amir Goldkorn; Mark G Garzotto; Philip C Mack; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Michael A Carducci; J Paul Monk; David I Quinn
Journal:  Clin Genitourin Cancer       Date:  2017-05-10       Impact factor: 2.872

2.  Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer.

Authors:  Guru Sonpavde; Ankit Madan; Mary K Baker; Jori E May; Gurudatta Naik; Sejong Bae
Journal:  Clin Genitourin Cancer       Date:  2017-04-26       Impact factor: 2.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.